The NASDAQ OMX Group, Inc., recently completed its acquisition of Willkie Farr & Gallagher LLP client The Philadelphia Stock Exchange, Inc. (PHLX) for an aggregate purchase price of $695 million.PHLX is the third largest options market in the U.S. and the nation's oldest stock exchange, having been founded in 1790.The deal was handled by a multidisciplinary Willkie team including partners Michael A. Schwartz, Tariq Mundiya, Frank Daniele and David Rubinsky
It has been announced that Willkie client Teva Pharmaceutical Industries Ltd. will purchase Barr Pharmaceuticals Inc. for $8.9 billion, including $1.5 billion of Barr debt. Teva, based in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. Willkie represented Teva in its acquisitions of CoGenesys Inc., and Bentley Pharmaceuticals Inc., earlier this year.
The transaction was handled by partners Peter Jakes, Jeffrey Hochman, David Rubinsky, Christopher Peters, William Rooney, Jochen Winter, Jacques-Phillippe Gunther and David Tayar; national partner Stefan Joergens; special counsels David Park and Jonathan Konoff.
Willkie served as special investment management counsel to Kohlberg Kravis Roberts & Co., in connection with KKR's agreement to acquire KKR Private Equity Investors, L.P. ("KPE"). Under the terms of the transaction, KKR will become publicly listed on the New York Stock Exchange. KKR, established in 1976, is a leading global asset manager focused on managing funds that make private equity investments in North America, Europe and Asia. The transaction is being handled by partners Barry Barbash and James Silk, and associate Marc Ponchione.